Adocia (ADOC) - Total Liabilities
Based on the latest financial reports, Adocia (ADOC) has total liabilities worth €27.86 Million EUR (≈ $32.57 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ADOC cash flow conversion to assess how effectively this company generates cash.
Adocia - Total Liabilities Trend (2008–2024)
This chart illustrates how Adocia's total liabilities have evolved over time, based on quarterly financial data. Check Adocia asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Adocia Competitors by Total Liabilities
The table below lists competitors of Adocia ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ruby Tech
TWO:8048
|
Taiwan | NT$298.62 Million |
|
Powerlong Real Estate Holdings Limited
F:PW5
|
Germany | €134.24 Billion |
|
Gateway Mining Ltd
AU:GML
|
Australia | AU$359.65K |
|
Bombay Super Hybrid Seeds Limited
NSE:BSHSL
|
India | Rs435.70 Million |
|
ITEK Inc
KQ:119830
|
Korea | ₩47.77 Billion |
|
Amica S.A.
WAR:AMC
|
Poland | zł930.90 Million |
|
Malindo Feedmill Tbk
JK:MAIN
|
Indonesia | Rp2.64 Trillion |
|
Renascor Resources Ltd
AU:RNU
|
Australia | AU$3.83 Million |
Liability Composition Analysis (2008–2024)
This chart breaks down Adocia's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Adocia.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -45.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Adocia's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Adocia (2008–2024)
The table below shows the annual total liabilities of Adocia from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €30.11 Million ≈ $35.20 Million |
-5.53% |
| 2023-12-31 | €31.87 Million ≈ $37.26 Million |
-26.88% |
| 2022-12-31 | €43.58 Million ≈ $50.95 Million |
-0.65% |
| 2021-12-31 | €43.87 Million ≈ $51.29 Million |
+12.97% |
| 2020-12-31 | €38.83 Million ≈ $45.40 Million |
+14.50% |
| 2019-12-31 | €33.91 Million ≈ $39.65 Million |
+40.17% |
| 2018-12-31 | €24.20 Million ≈ $28.29 Million |
+43.13% |
| 2017-12-31 | €16.90 Million ≈ $19.76 Million |
-53.09% |
| 2016-12-31 | €36.04 Million ≈ $42.13 Million |
-12.20% |
| 2015-12-31 | €41.04 Million ≈ $47.98 Million |
-17.98% |
| 2014-12-31 | €50.04 Million ≈ $58.50 Million |
+793.71% |
| 2013-12-31 | €5.60 Million ≈ $6.55 Million |
-58.83% |
| 2012-12-31 | €13.60 Million ≈ $15.90 Million |
+2.20% |
| 2011-12-31 | €13.31 Million ≈ $15.56 Million |
+204.07% |
| 2010-12-31 | €4.38 Million ≈ $5.12 Million |
+0.74% |
| 2009-12-31 | €4.34 Million ≈ $5.08 Million |
+17.79% |
| 2008-12-31 | €3.69 Million ≈ $4.31 Million |
-- |
About Adocia
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of act… Read more